IRLAB Reports Positive Results from the Second Part of a Phase I Study with IRL757
GOTHENBURG, SE / / May 28, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - Gothenburg, Sweden, May 28, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company that discovers and develops new treatments for Parkinson's disease, today announces the company has successfully completed the second and final part of its clinical Phase I study, in which the drug candidate IRL757, being developed for the treatment of apathy, was administered in multiple ascending doses (MAD). The results show that IRL757 is well absorbed and provides good exposure in the body following ten days of dosing. All participants completed the study, and no serious adverse events were recorded. The safety, tolerability and pharmacokinetic profile of IRL757 support continued clinical development.
"We are very pleased that IRL757 is well absorbed and provides good exposure in the body while demonstrating excellent tolerability and a favorable safety profile. These results give us a strong foundation for the continued clinical development of the drug candidate, which has the potential to treat and counteract apathy in millions of patients with neurodegenerative diseases," says Dr. Joakim Tedroff, MD, Chief Medical Officer at IRLAB.
The Phase I study has been funded by The Michael J. Fox Foundation for Parkinson's Research (MJFF) through a grant of just over SEK 20 million. MJFF is the world's largest non-profit funder of Parkinson's disease research, and the organization's support for IRL757 means a strong external validation of the project's goals and potential.
Based on the positive results from the completed Phase I studies, a clinical Phase Ib study in Parkinson's disease and apathy has been initiated in cooperation with The McQuade Center for Strategic Research and Development (MSRD), a member of the global Otsuka family of pharmaceutical companies. The first patients are expected to be enrolled in the study in the second half of 2025. IRLAB and MSRD formed a collaboration in May 2024 to advance IRL757 through proof-of-concept trials as a potential treatment of apathy.
Apathy is characterized by indifference, resignation and a lack of response to what is happening in the outside world. The condition often leads to significant disability and caregiver distress, affecting a substantial proportion of people living with Parkinson's, Alzheimer's and other diseases related to the central nervous system. Currently, there are no drugs on the market to treat apathy. IRLAB's drug candidate IRL757 has shown positive effects in several preclinical models of cognitive function, including improved motivation. This effect is believed to be associated with the drug candidate's unique ability to counteract disturbances in central nervous system nerve signaling proposed to underly apathy in several neurological conditions.
Om Fas I-studienThe Phase I study consists of two parts and aims to document the safety, tolerability and pharmacokinetic properties of IRL757 in healthy subjects. In the first part of the study, single ascending doses of the drug candidate are administered (SAD) and in the second part, multiple ascending doses are given (MAD). In addition, the possible influence of concomitant food intake will be documented.
For more information
Kristina Torfgård, CEOPhone: +46 730 60 70 99E-mail: kristina.torfgard@irlab.se
About IRL757
The drug candidate IRL757 is being developed as a treatment for apathy in Parkinson's disease and other neurological conditions. Apathy, a widespread and debilitating issue, affects over 20 million people in the U.S. and Europe alone without a currently available treatment. The prevalence is high, occurring in 1.1-4 million people (20-70 percent) being treated with Parkinson's in the eight major markets (China, EU5, Japan, and the US), and in 4.9-6.7 million people (43-59 percent) being treated for Alzheimer's disease in the ten major markets (Canada, China, EU5, Japan, South Korea, and the US). IRL757 has the potential to become the first treatment for apathy. The efficacy of IRL757 is thought to be linked to its unique ability to reverse disruption in cortical to sub-cortical nerve signalling, a key factor believed to contribute to apathy in neurological disorders.
About IRLAB
IRLAB discovers and develops a portfolio of transformative treatments for all stages of Parkinson's disease. The company originates from Nobel Laureate Prof Arvid Carlsson's research group and the discovery of a link between brain neurotransmitter disorders and brain diseases. Mesdopetam (IRL790), under development for treating levodopa-induced dyskinesias, has completed Phase IIb and is in preparation for Phase III. Pirepemat (IRL752), currently in Phase IIb, is being evaluated for its effect on balance and fall frequency in Parkinson's disease. IRL757, a compound being developed for the treatment of apathy in neurodegenerative disorders, is in Phase I. In addition, the company is developing two preclinical programs, IRL942 and IRL1117, towards Phase I studies. IRLAB's pipeline has been generated by the company's proprietary systems biology-based research platform Integrative Screening Process (ISP). Headquartered in Sweden, IRLAB is listed on Nasdaq Stockholm (IRLAB A). For more information, please visit www.irlab.se .
Attachments
IRLAB reports positive results from the second part of a Phase I study with IRL757
SOURCE: IRLAB Therapeutics
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
San Francisco Chronicle
7 hours ago
- San Francisco Chronicle
Does coffee boost longevity? 47,000 women were studied for 30 years to find out
Drinking moderate amounts of coffee in midlife may boost healthy aging decades later, according to a study presented this week at the annual meeting of the American Society for Nutrition. The findings add to the existing body of research showing there may be health and longevity benefits to consuming coffee. Most of these studies are observational and do not directly show that consuming coffee necessarily causes better health, just that people who drink coffee often tend to be healthier — as measured by such metrics as lower cardiovascular mortality, lower risk of some cancers and lower risk of Type 2 diabetes. The analysis, which followed more than 47,000 women over about 30 years, found that those who drank coffee during midlife, ages 45 to 60, were more likely to exhibit healthy aging later in life. On average, they consumed 315 milligrams of caffeine a day, the equivalent to about three small cups of coffee. The researchers defined healthy aging as being at least 70 years old and free from 11 major chronic diseases — including heart disease, Type 2 diabetes, cancer and Parkinson's disease — with no major mental health or cognitive impairment or memory problems. The study followed female nurses starting in 1984 and asked them to fill out questionnaires about their consumption of coffee, tea and soda. By 2016, about 3,700 women were considered part of the healthy aging group. Within that group, each extra cup of coffee a day was linked to a 2% to 5% higher chance of doing well later in life, up to five small cups a day. The same link between coffee consumption and better health in later life was not found among women who drank tea, soda or decaffeinated coffee. 'While past studies have linked coffee to individual health outcomes, our study is the first to assess coffee's impact across multiple domains of aging over three decades,' Sara Mahdavi, an adjunct professor of nutritional sciences at the University of Toronto who led the study, said in a statement. 'The findings suggest that caffeinated coffee — not tea or decaf — may uniquely support aging trajectories that preserve both mental and physical function.' The study did not examine why caffeinated coffee and not other caffeinated beverages was linked to healthy aging. But previous research suggests that coffee contains antioxidants like polyphenols, which may help the body lower inflammation, reduce oxidative stress on cells and fight diseases. The analysis accounted for other factors that influence healthy aging including body weight, smoking, alcohol use, physical activity, education level and protein in the diet. 'The takeaway is not that people should start drinking coffee for the sake of longevity, nor that more is better,' Mahdavi said. 'What we found is that moderate caffeinated coffee consumption — approximately 1 to 3 cups per day — was associated with a modestly higher likelihood of healthy aging over time.'
Axios
19 hours ago
- Axios
California high-speed rail project faces reckoning
California's high-speed rail project was billed as the future of transportation, but with President Trump moving to pull $4 billion in federal funds, its future remains precarious. Why it matters: The system was initially slated for completion in 2020. But because of funding challenges and other delays, construction has not started beyond the 171-mile segment in the Central Valley, which would connect San Francisco to Los Angeles and Anaheim. Driving the news: In a 310-page compliance review released this week, the Federal Railroad Administration (FRA) called the project a "story of broken promises." Citing mismanagement of budget shortfalls, missed deadlines, costly change orders, and the "lack of a credible plan" to close the $7 billion funding gap needed for the Central Valley segment, the FRA said it sees "no viable path" to a completed system. The California High Speed Rail Authority (CHRSA) has 37 days to respond to the review before the FRA moves to withdraw federal grants. The other side: The CHSRA said in a statement after the report's release that it "strongly disagrees with the FRA's conclusions, which are misguided and do not reflect the substantial progress made." It added, "The Authority will fully address and correct the record in our formal response." Sens. Adam Schiff and Alex Padilla also issued a statement calling the announcement "devastating" for Californians. Between the lines: One reason for the missed deadlines is a California policy that requires utility companies to review and approve relocation plans before public utility infrastructure can be moved to accommodate construction for a government project. The CHSRA inspector general said in a February assessment that there is "little incentive" for owners to do so in a timely manner and that CHSRA should instead work with legislators to revise state laws to minimize third-party delays. By the numbers: Spending for the project totals $14 billion, with 82% from the state and 18% from federal funds. The entire budget for the system is almost $100 billion higher than the original $33 billion estimate provided in 2008, when voters approved the ballot to initiate the project. Yes, but: Californians still largely support the endeavor. A recent Politico-UC Berkeley poll found that 67% of registered voters in the state back the project, compared to 33% who oppose. It's especially well-regarded in the Central Valley, where it's helped create more than 15,000 jobs, per the governor's office.
Yahoo
20 hours ago
- Yahoo
Pan American Energy Closes Debt Settlement Transactions
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, June 06, 2025 (GLOBE NEWSWIRE) -- Pan American Energy Corp. (CSE: PNRG | FRA: SS60) ('Pan American' or the 'Company') announces, further to its news release of May 29, 2024, that it has issued, 205,841 common shares in the capital of the Company (the 'Settlement Shares'), at a deemed value of $0.20 per Settlement Share, in full and final settlement of accrued and outstanding debt to certain creditors of the Company in the aggregate amount of $441,168.50 (the 'Debt Settlement Transactions'). All securities issued pursuant to the Debt Settlement Transactions are subject to a statutory hold period expiring on October 7, 2025, being the date that is four months and one day from the date of issuance in accordance with applicable Canadian securities legislation. About Pan American Energy Corp. Pan American Energy Corp. (CSE: PNRG) (FSE: SS60) is an exploration stage company engaged principally in the acquisition, exploration and development of mineral properties containing battery metals in North America. The Company has executed an option agreement in Canada with Magabra Resources pursuant to which it has acquired a 75% interest in the Big Mack Lithium Project, 80 km north of Kenora, Ontario. The Company can earn an additional 15% interest in Big Mack, for a total of 90% interest. To register for investor updates, please visit On Behalf of the Board of Directors Adrian LamoureauxChief Executive Officer Contact Phone:(587)885-5970Email: info@ Cautionary Note Regarding Forward-Looking Statements Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words 'could', 'intend', 'expect', 'believe', 'will', 'projected', 'estimated' and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. In particular, this press release contains forward-looking information relating to, among other things, the Debt Settlement Transactions, including the receipt of all necessary regulatory and other approvals. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information, including the assumption that the Canadian Securities Exchange will accept the terms of the Debt Settlement Transactions and that the Debt Settlement Transaction will proceed as currently anticipated. Those assumptions and factors are based on information currently available to the Company. Although such statements are based on reasonable assumptions of the Company's management, there can be no assurance that any conclusions or forecasts will prove to be accurate. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors include, among other things, the risk that the Debt Settlement Transaction does not close, including as a result of failure to receive the approval of the Canadian Securities Exchange for the Debt Settlement Transaction; risks inherent in the exploration and development of mineral deposits, including risks relating to changes in project parameters as plans continue to be redefined and the risk that exploration and development activities will cost more than the amount budgeted for such activities by the Company; access and supply risks; operational risks; regulatory risks, including risks relating to the acquisition of the necessary licenses and permits; financing, capitalization and liquidity risks; and title and environmental risks. The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.
